Fresenius Medical Care AG & Co. KGaA (FMS) Projected to Post Quarterly Earnings on Tuesday

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is anticipated to announce its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect the company to announce earnings of $0.58 per share and revenue of $4.7221 billion for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:00 AM ET.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its earnings results on Tuesday, August 5th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.50 by $0.02. The company had revenue of $5.54 billion during the quarter, compared to analysts’ expectations of $5 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. On average, analysts expect Fresenius Medical Care AG & Co. KGaA to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Fresenius Medical Care AG & Co. KGaA Stock Performance

NYSE FMS opened at $26.83 on Monday. The firm has a 50-day moving average of $26.06 and a 200-day moving average of $26.57. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.08 and a current ratio of 1.44. The stock has a market cap of $15.74 billion, a PE ratio of 21.99, a P/E/G ratio of 0.64 and a beta of 0.92. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $19.26 and a 52-week high of $30.46.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. UBS Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research note on Wednesday, October 15th. Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Bank of America cut shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research note on Wednesday, October 15th. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 12th. Finally, Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 25th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $27.80.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% in the 2nd quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock valued at $9,637,000 after buying an additional 248,477 shares in the last quarter. Qube Research & Technologies Ltd raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 175.3% in the 2nd quarter. Qube Research & Technologies Ltd now owns 199,563 shares of the company’s stock valued at $5,702,000 after buying an additional 127,073 shares in the last quarter. Quantinno Capital Management LP grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 2.9% during the 2nd quarter. Quantinno Capital Management LP now owns 182,222 shares of the company’s stock valued at $5,206,000 after purchasing an additional 5,078 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 10.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 67,703 shares of the company’s stock valued at $1,934,000 after purchasing an additional 6,456 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 616.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 62,815 shares of the company’s stock valued at $1,795,000 after purchasing an additional 54,048 shares during the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.